Drug Trial Radar · NCT03332095
Evaluating the Pharmacokinetics, Safety, and Tolerability of Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) in HIV-1-Infected Children and Adolescents
Last checked: Nov 19, 2026Latest source record: Feb 14, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
55
Actual
Start
Jul 2, 2018
Primary completion
Aug 19, 2020
Study completion May 25, 2022
Sponsor
- Sponsor type
- NIH
- First posted
- Nov 6, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to evaluate the pharmacokinetics, safety, and tolerability of doravirine (also called MK-1439 or DOR) and doravirine/lamivudine/tenofovir disoproxil fumarate (also called MK-1439A or DOR/3TC/TDF) in HIV-1-infected children and adolescents.
Conditions
- HIV Infections
Interventions
Doravirine (DOR)Drug
100 mg of DOR administered orally
Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF)Drug
DOR/3TC/TDF administered orally as a fixed-dose combination (as a tablet, 100 mg/300 mg/300 mg) once daily
Antiretroviral (ARV) medicationsDrug
Participants in Cohort 1 received a combination of dolutegravir (DTG) or raltegravir (RAL) plus two nucleoside reverse transcriptase inhibitors (NRTIs). The ARV drugs were prescribed by participants' own health care providers and were not provided by the study.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pharmacokinetic (PK) Parameter: Single-dose Area-under-the-curve (AUC0-∞) of Doravirine (DOR) (Cohort 1)Time frame: Measured during the entry (day 0) visit. Blood samples were drawn at pre-dose, and at 1, 2, 4, 8, 12, 24, 48 and 72 hours post-dose.
- PK Parameter: Single-dose Maximum Concentration (Cmax) of DOR (Cohort 1)Time frame: Measured during the entry (day 0) visit. Blood samples were drawn at pre-dose, and at 1, 2, 4, 8, 12, 24, 48 and 72 hours post-dose.
- PK Parameter: Single-dose 24 Hour-concentration (C24hr) of DOR (Cohort 1)Time frame: Measured during the entry (day 0) visit. Blood samples were drawn at pre-dose, and at 1, 2, 4, 8, 12, 24, 48 and 72 hours post-dose.
- Percentage of Participants With Grade 3 or Higher Adverse Events (AEs) Assessed as Related to Study DrugTime frame: Cohort 1: Measured from Day 0 through Week 2; Cohort 2: Measured from Day 0 through Week 24.
- Percentage of Participants With Serious Adverse Events (SAEs) Assessed as Related to Study DrugTime frame: Cohort 1: Measured from Day 0 through Week 2; Cohort 2: Measured from Day 0 through Week 24.
- Percentage of Participants With Permanent Discontinuation of Study Drug Due to Adverse Events Assessed as Related to Study DrugTime frame: Cohort 1: Measured from Day 0 through Week 2; Cohort 2: Measured from Day 0 through Week 24.
- Percentage of Participants With Grade 5 Adverse Events (Death) Regardless of Relationship to Study DrugTime frame: Cohort 1: Measured from Day 0 through Week 2; Cohort 2: Measured from Day 0 through Week 24.
Locations
8 sites in 3 countries. Site status is shown where the registry gives one.
Univ. of Colorado Denver NICHD CRS
Aurora, Colorado
Boston Medical Center Ped. HIV Program NICHD CRS
Boston, Massachusetts
St. Jude Children's Research Hospital CRS
Memphis, Tennessee
Seattle Children's Research Institute CRS
Seattle, Washington
Soweto IMPAACT CRS
Johannesburg, Gauteng, South Africa
Chiangrai Prachanukroh Hospital NICHD CRS
Chiang Mai, Thailand
Chiang Mai University HIV Treatment (CMU HIV Treatment) CRS
Chiang Mai, Thailand
Siriraj Hospital ,Mahidol University NICHD CRS
Bangkok, Bangkoknoi, Thailand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.